Fibrosarcoma

Hydrophobic weakly basic drugs, such as doxorubicin and sunitinib, are currently key components of cancer chemotherapy...Co-treatment with doxorubicin and chloroquine, a well-established lysosomotropic agent, results in the increased lysosomal volume under both normoxic and hypoxic conditions...A similar effect, lysosomal volume expansion and enhanced degradative capacity in response to doxorubicin, was also observed in the human fibrosarcoma cell line HT1080. In summary, this study provides the first evidence that doxorubicin directly modulates lysosomal parameters in the tumor cell lines under varying oxygen concentrations.

Our findings demonstrate that the MCTO mutation results in MAFB protein accumulation and leads to the development of FSGS in mice. These findings identify the MAFB-PI3K/AKT pathway as a key mechanism underlying MCTO-associated nephropathy.

HMGA2 may be more readily implemented than ETV4 and DUX4, even in non-specialized hospitals. Thus, HMGA2 immunohistochemistry is a useful adjunct for CRS diagnosis. HMGA2 expression in CRS and other small round or epithelioid cell tumours should be tested in a larger series, particularly in non-DUX4 CRS and ATXN1/ATXN1L-rearranged sarcomas.

Our findings suggest that c-MAF/Slc40a1 may represent a promising prevention target for SAE.

Here, we identify the acyl-CoA-binding protein/diazepam-binding inhibitor (ACBP/DBI) as a critical effector of the GC-induced suppression of tumor immunosurveillance and immunotherapy efficacy...The immunosuppressive activity of GCs and the immunostimulatory function of anti-ACBP/DBI mAb converge on Tsc22d3 expression in myeloid cells, as shown by loss-of-function experiments in myeloid-specific Tsc22d3-deficient mice. These findings reveal ACBP/DBI as a central mediator of GC-induced immune evasion and suggest its neutralization as a therapeutic strategy to restore anticancer immunity during endogenous or iatrogenic GC exposure.

P2/3, N=140, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026

EPS15/EPS15L1::KLF17-rearranged sarcoma has distinctive histologic findings, including diffuse MUC4 expression. Recognition is clinically important given its potential for late recurrence and metastasis.

P3, N=400, Recruiting, Day One Biopharmaceuticals, Inc. | Trial completion date: Mar 2030 --> Jun 2031 | Trial primary completion date: Feb 2026 --> Jun 2027

This review aims to highlight the key clinicopathologic features of these tumors to facilitate accurate diagnosis, discuss ancillary studies that assist in navigating the differential diagnoses, and outline strategies to avoid common diagnostic pitfalls. Finally, we emphasize when molecular characterization may be necessary to guide diagnosis and support appropriate clinical management.

The results demonstrated that c-Myc expression was significantly higher in grade III than in grade II and I (p ≤ 0.05) fibrosarcomas regarding protein and gene levels. In summary, this work provides evidence for the high expression of c-Myc in canine and feline fibrosarcomas and proposes a supposed relationship with poor prognoses as determined by grading systems.

Radiation therapy and imatinib may be considered for unresectable tumors, and we advise that COL1A1-PDGFB fusion is confirmed before starting imatinib...Advances in organoid models and single-cell RNA sequencing have improved understanding of the tumor microenvironment. However, racial disparities in diagnosis and treatment emphasize the need for a high index of suspicion in skin of color patients to reduce misdiagnosis and delays in care.

P1, N=14, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027